Clinico-epidemiological Study of Locally Advanced Nasopharyngeal Carcinoma | ||||
| SECI Oncology Journal | ||||
| Article 1, Volume 10, Issue 2, May 2022, Page 44-55 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: As its unique clinical and biological behaviour, nasopharyngeal carcinoma (NPC) is a highly chemo and radio sensitive tumour. The gold standard of therapy for nasopharyngeal cancer that has progressed locally cancer (LANPC) (stages III-IVA) is concurrent chemo-radiation (CCRT), but still not well defined the exact timing and sequence of chemotherapy. It's debatable if induction and adjuvant chemotherapy play a function. Here, we'll look at clinico-epidemiological characteristics of LANPC patients, as well as survivability benefits and prognostic factors [Disease free survival (DFS) & the overall survival (OS)] of various options of treatment. Objectives: to investigate the clinico-epidemiological characteristics of individuals with Naso-pharyngeal cancer has progressed locally cancer and to assess variables of prognosis and the survival advantages [Disease free survival (DFS) & Overall survival (OS)] of various options of treatment in NPC. Patients and Methods: From January 2008 to December 2017, patients diagnosed as locally advanced nasopharyngeal cancer attended to Mansoura University Hospital, Clinical Oncology and Nuclear Medicine Department and Meetghamr Oncology Centre were studied retrospectively. Results: The most important predictive factor for NPC appears to be clinical stage and treatment strategy. Both the 5-year OS and PFS markedly decrease as the stage increases. Patients with stages III and IVa had a 5-year OS rate of 69 percent and a 5-years progression-free survival (PFS) rate of 57 percent. The 5- year OS rates for the groups that received radiotherapy plus chemotherapy (CCRT + NAC) or Adjuvant chemotherapy, as well as the group that received only CCRT, were 80.3 percent, 72.7 percent, and 39 percent, respectively (P=0.001). The following were the 5-year PFS rates in these groups: 77.95 percentage 73.579percentage 15.5 percent (P=0.043) of the population The addition of neo adjuvant chemotherapy to patients with stage III, stage IVa NPC can considerably improve both OS and PFS. Conclusion: Finally, in cases with LANPC, disease stage and treatment protocol are crucial prognostic markers for survival. Induction chemotherapy and CCRT both enhance overall survival. Patients who receive 3DCRT had a longer OS and PFS than those who receive 2DRT, and the radiation toxicity is substantially lower with 3DCRT | ||||
| Keywords | ||||
| concurrent chemoradiotherapy; nasopharyngeal carcinoma; overall survival | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 85 |
||||
